Chromocell Therapeutics Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the Year Ended | For the Year Ended | |
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| OPERATING EXPENSES | ||
| General and administrative expenses | $2,738,948 | $1,098,848 |
| Research and development | 2,579,418 | 391,730 |
| Professional fees | 1,543,918 | 827,581 |
| Total operating expenses | 6,862,284 | 2,318,159 |
| NET LOSS FROM OPERATIONS | (6,862,284) | (2,318,159) |
| OTHER (EXPENSE) INCOME | ||
| Interest expense | (518,509) | (140,430) |
| Total other (expense) income | (518,509) | (140,430) |
| Net loss before provision for income taxes | (7,380,793) | (2,458,589) |
| Provision for income taxes | — | — |
| NET LOSS | $(7,380,793) | $(2,458,589) |
| Net loss per common share - basic and diluted | $5,78) | $5,65) |
| Weighted average number of common shares outstanding during the year - basic and diluted | 1,276,543 | 435,312 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.